Reuters logo
BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir
June 22, 2017 / 11:32 AM / 3 months ago

BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir

June 22 (Reuters) - Durect Corp

* Durect completes enrollment in Persist, phase 3 trial for Posimir

* Durect - Durect remains responsible for completion of ongoing persist phase 3 clinical trial for Posimir as well as FDA interactions through approval

* Durect Corp - phase 3 trial for Posimir top-line data on track for Q4 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below